(IRTC) iRhythm Technologies - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 3.820m USD | Total Return: 10.3% in 12m

Stock Cardiac Monitoring, ECG Systems, Health Technology
Total Rating 41
Safety 54
Buy Signal -0.68
Medical Devices -6.2
Health Care Equipment -3.7
Market Cap: 3,820m
Avg Trading Vol: 70.2M USD
ATR: 4.93%
Peers RS (IBD): 22.0
Risk 5d forecast
Volatility53.5%
Rel. Tail Risk-6.92%
Reward TTM
Sharpe Ratio0.39
Alpha-8.18
Character TTM
Beta1.155
Beta Downside2.791
Drawdowns 3y
Max DD59.15%
CAGR/Max DD-0.04
EPS (Earnings per Share) EPS (Earnings per Share) of IRTC over the last years for every Quarter: "2021-03": -0.95, "2021-06": -0.59, "2021-09": -0.81, "2021-12": -1.1, "2022-03": -0.8, "2022-06": -0.8, "2022-09": -0.63, "2022-12": -0.67, "2023-03": -1.1, "2023-06": -0.61, "2023-09": -0.89, "2023-12": -1.26, "2024-03": -1.23, "2024-06": -0.61, "2024-09": -1.26, "2024-12": 0.01, "2025-03": -0.95, "2025-06": -0.32, "2025-09": 0.06, "2025-12": 0.17, "2026-03": 0,
EPS CAGR: 28.00%
EPS Trend: 61.3%
Last SUE: 1.45
Qual. Beats: 1
Revenue Revenue of IRTC over the last years for every Quarter: 2021-03: 74.311, 2021-06: 81.278, 2021-09: 85.432, 2021-12: 81.804, 2022-03: 92.378, 2022-06: 102.051, 2022-09: 103.875, 2022-12: 112.617, 2023-03: 111.436, 2023-06: 124.13, 2023-09: 124.604, 2023-12: 132.511, 2024-03: 131.929, 2024-06: 148.047, 2024-09: 147.538, 2024-12: 164.325, 2025-03: 158.677, 2025-06: 186.687, 2025-09: 192.884, 2025-12: 208.89, 2026-03: null,
Rev. CAGR: 24.31%
Rev. Trend: 99.0%
Last SUE: 1.60
Qual. Beats: 5
Risks
Technicals: choppy
Description: IRTC iRhythm Technologies

iRhythm Technologies Inc. (IRTC) is a digital healthcare company specializing in ambulatory cardiac monitoring services within the Health Care Equipment sector. This sector focuses on medical devices and equipment used for diagnosis and treatment.

The company provides Zio brand services and systems for diagnosing cardiac arrhythmias. These offerings include long-term and short-term continuous monitoring, mobile cardiac telemetry, and prescription-only remote ECG monitoring systems like Zio Monitor, Zio XT, and Zio AT. These devices record heart electrical signals for extended periods, typically up to 14 days.

IRTCs business model involves device-based technology for remote patient monitoring. The company has a development collaboration with BioIS to integrate additional physiological monitoring technologies into its cardiac monitoring products. Further research on ValueRay can provide deeper insights into IRTCs market position and financial performance.

Headlines to Watch Out For
  • Reimbursement rates for Zio services impact revenue
  • Increased adoption of Zio products drives sales
  • Competitive landscape pressures market share
  • Regulatory changes affect product approval timelines
Piotroski VR‑10 (Strict) 4.5
Net Income: -44.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA 6.66 > 1.0
NWC/Revenue: 73.73% < 20% (prev 90.38%; Δ -16.65% < -1%)
CFO/TA 0.08 > 3% & CFO 80.9m > Net Income -44.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.63 > 1.5 & < 3
Outstanding Shares: last quarter (33.3m) vs 12m ago 6.35% < -2%
Gross Margin: 70.57% > 18% (prev 0.69%; Δ 6.99k% > 0.5%)
Asset Turnover: 76.57% > 50% (prev 63.54%; Δ 13.03% > 0%)
Interest Coverage Ratio: -2.43 > 6 (EBITDA TTM -7.87m / Interest Expense TTM 13.2m)
Altman Z'' -0.22
A: 0.54 (Total Current Assets 702.8m - Total Current Liabilities 151.9m) / Total Assets 1.02b
B: -0.79 (Retained Earnings -803.4m / Total Assets 1.02b)
C: -0.03 (EBIT TTM -32.0m / Avg Total Assets 975.7m)
D: -0.93 (Book Value of Equity -803.0m / Total Liabilities 867.3m)
Altman-Z'' Score: -0.22 = B
Beneish M -3.19
DSRI: 0.75 (Receivables 75.7m/79.9m, Revenue 747.1m/591.8m)
GMI: 0.98 (GM 70.57% / 68.86%)
AQI: 1.00 (AQ_t 0.12 / AQ_t-1 0.12)
SGI: 1.26 (Revenue 747.1m / 591.8m)
TATA: -0.12 (NI -44.6m - CFO 80.9m) / TA 1.02b)
Beneish M-Score: -3.19 (Cap -4..+1) = AA
What is the price of IRTC shares? As of April 05, 2026, the stock is trading at USD 118.02 with a total of 404,763 shares traded.
Over the past week, the price has changed by -1.10%, over one month by -7.19%, over three months by -36.66% and over the past year by +10.27%.
Is IRTC a buy, sell or hold? iRhythm Technologies has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy IRTC.
  • StrongBuy: 9
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the IRTC price?
Wallstreet Target Price 211.4 79.1%
Analysts Target Price 211.4 79.1%
IRTC Fundamental Data Overview as of 03 April 2026
P/S = 5.1135
P/B = 24.9866
Revenue TTM = 747.1m USD
EBIT TTM = -32.0m USD
EBITDA TTM = -7.87m USD
Long Term Debt = 649.5m USD (from longTermDebt, last quarter)
Short Term Debt = 16.7m USD (from shortTermDebt, last quarter)
Debt = 731.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 495.2m USD (from netDebt column, last quarter)
Enterprise Value = 3.97b USD (3.82b + Debt 731.2m - CCE 583.8m)
Interest Coverage Ratio = -2.43 (Ebit TTM -32.0m / Interest Expense TTM 13.2m)
EV/FCF = 114.9x (Enterprise Value 3.97b / FCF TTM 34.5m)
FCF Yield = 0.87% (FCF TTM 34.5m / Enterprise Value 3.97b)
FCF Margin = 4.62% (FCF TTM 34.5m / Revenue TTM 747.1m)
Net Margin = -5.96% (Net Income TTM -44.6m / Revenue TTM 747.1m)
Gross Margin = 70.57% ((Revenue TTM 747.1m - Cost of Revenue TTM 219.9m) / Revenue TTM)
Gross Margin QoQ = 70.88% (prev 71.09%)
Tobins Q-Ratio = 3.89 (Enterprise Value 3.97b / Total Assets 1.02b)
Interest Expense / Debt = 0.45% (Interest Expense 3.32m / Debt 731.2m)
Taxrate = 7.42% (447k / 6.03m)
NOPAT = -29.6m (EBIT -32.0m * (1 - 7.42%)) [loss with tax shield]
Current Ratio = 4.63 (Total Current Assets 702.8m / Total Current Liabilities 151.9m)
Debt / Equity = 4.79 (Debt 731.2m / totalStockholderEquity, last quarter 152.7m)
 Debt / EBITDA = -62.93 (negative EBITDA) (Net Debt 495.2m / EBITDA -7.87m)
 Debt / FCF = 14.34 (Net Debt 495.2m / FCF TTM 34.5m)
Total Stockholder Equity = 116.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.57% (Net Income -44.6m / Total Assets 1.02b)
RoE = -38.33% (Net Income TTM -44.6m / Total Stockholder Equity 116.2m)
RoCE = -4.18% (EBIT -32.0m / Capital Employed (Equity 116.2m + L.T.Debt 649.5m))
 RoIC = -3.88% (negative operating profit) (NOPAT -29.6m / Invested Capital 764.6m)
 WACC = 8.50% (E(3.82b)/V(4.55b) * Re(10.05%) + D(731.2m)/V(4.55b) * Rd(0.45%) * (1-Tc(0.07)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.20%
[DCF] Terminal Value 72.04% ; FCFF base≈34.5m ; Y1≈26.7m ; Y5≈16.9m
 [DCF] Fair Price = N/A (negative equity: EV 292.8m - Net Debt 495.2m = -202.4m; debt exceeds intrinsic value)
 EPS Correlation: 61.29 | EPS CAGR: 28.00% | SUE: 1.45 | # QB: 1
Revenue Correlation: 98.98 | Revenue CAGR: 24.31% | SUE: 1.60 | # QB: 5
EPS next Quarter (2026-06-30): EPS=-0.10 | Chg7d=+0.000 | Chg30d=-0.030 | Revisions Net=-2 | Analysts=9
EPS current Year (2026-12-31): EPS=-0.27 | Chg7d=+0.000 | Chg30d=+0.008 | Revisions Net=+2 | Growth EPS=+74.2% | Growth Revenue=+17.2%
EPS next Year (2027-12-31): EPS=0.84 | Chg7d=+0.000 | Chg30d=+0.166 | Revisions Net=+2 | Growth EPS=+415.2% | Growth Revenue=+15.9%
[Analyst] Revisions Ratio: -0.25 (3 Up / 5 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle